Full text is available at the source.
Abstract
Obesity-related heart failure with preserved ejection fraction (HFpEF) is increasingly recognized as a multiorgan syndrome.
- Obesity contributes to HFpEF through metabolic dysfunction, systemic inflammation, and increased fat around organs.
- Higher levels of visceral and epicardial fat are associated with heart, liver, and kidney involvement.
- GLP-1 receptor agonists may improve symptoms, exercise capacity, and reduce heart failure events in obesity-related HFpEF.
- Incretin-based therapies could lead to decreased ectopic fat deposits and beneficial changes in heart structure.
- Future clinical trials are needed to explore the mechanisms of benefit and the role of weight-reduction therapies in this condition.
Simplified